<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4092">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290978</url>
  </required_header>
  <id_info>
    <org_study_id>05-011219</org_study_id>
    <nct_id>NCT01290978</nct_id>
  </id_info>
  <brief_title>Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin</brief_title>
  <official_title>Prospective, Randomized Comparison of Two Presurgical Skin Antiseptic Preparations and Resultant Surgical Incise Drape Adhesion to Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cyberderm Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if presurgical antiseptic preparations affect how
      well surgical drapes adhere to skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adhesive incise drapes are often used to provide a physical sterile barrier between the
      surrounding skin and the open wound at the beginning of a surgery. This study sought to
      determine the effect of presurgical skin antiseptic preparation on the adhesion of various
      incise drapes to the skin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Drape Adhesion</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The peel force to remove the sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Assessment on Ioban, ActiGard, Steri-Drape 2 Application Sites Respectively</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual assessment on skin after samples were removed. scale: 0 (no skin reaction), 4 (severe skin reaction)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ChloraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Applied ChloraPrep on the application site per manufacturer's instruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DuraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply DuraPrep to the application site per manufacturer's instruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule</description>
    <arm_group_label>ChloraPrep</arm_group_label>
    <other_name>ChloraPrep® with Tint (Scrub Teal®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DuraPrep</intervention_name>
    <description>The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule</description>
    <arm_group_label>DuraPrep</arm_group_label>
    <other_name>3M™ DuraPrep™ Surgical Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is willing to sign the Research Consent form

          -  Healthy male or female subjects ages between 18 - 65

          -  Subject has agreed to be and appears to be compliant with requirements of the study

          -  Subject has a back (the product application site) of sufficient size, free of
             blemishes to comfortably fit 18 strips of 1/2&quot; x 3&quot; drape samples

          -  Subject is willing to have the back clipped or shaved if it has excessive hair

        Exclusion Criteria:

          -  Sensitivity/allergy to adhesive products (e.g. medical tapes)

          -  Sensitivity to the antimicrobial agent iodine, povidone iodine (PVPI), isopropyl
             alcohol (IPA), or chlorhexidine gluconate (CHG)

          -  Allergy to seafood

          -  History of psoriasis dermatitis, or any skin condition that might be exacerbated by
             the action of removing adhesive materials

          -  Active dermatitis (rash), sunburn, blemishes, broken skin, cuts, and/or infection on
             the subject's back

          -  History of diabetes

          -  Subject is currently pregnant or thinks she may be pregnant or is nursing

          -  Subject is receiving steroid-based anti-inflammatory or immunosuppressant drug
             therapy

          -  Subject is taking antihistamine medication

          -  Subject has been using moisturizers or other skin contact materials on the test sites
             for 24 hours prior to the start of the study

          -  Subject has a back problem that prohibits him or her from lying face downward for
             approximately 2 hours
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary L Grove, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cyberderm Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>cyberDERM Clinical Studies</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 16, 2013</lastchanged_date>
  <firstreceived_date>February 4, 2011</firstreceived_date>
  <firstreceived_results_date>January 29, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted between 22 Feb and 5 March 2010. Twenty-four male or female healthy volunteers between ages of 18 and 65 were screened for this study in order to ensure that at least 20 volunteers were enrolled. Volunteers were recruited from a pool of suburban men/women who met the exclusion/inclusion criteria.</recruitment_details>
      <pre_assignment_details>Volunteers who met the exclusion/inclusion criteria were required to undergo a 1-day washout period where they were not allowed to use any moisturizing products or other skin contact materials on their backs. Two subjects were screen failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ChloraPrep, DuraPrep</title>
          <description>Subject's back was visually divide into 2. Applied each prep per manufacturer's instruction on either right or left of back according to randomization schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A sample size of 18 subjects and 18 drape samples per subject was determined to provide 80% power to detect a difference of 20% for the drape by prep comparison. A minimum of 20 subjects was used to account for the uncertainty in variability.</population>
      <group_list>
        <group group_id="B1">
          <title>ChloraPrep , DuraPrep</title>
          <description>Subject's back was applied with 2 skin preps (ChloraPrep and DuraPrep), one on each side of subject's back per randomization schedule.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.4" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Eleven males and 11 females were enrolled into the study</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drape Adhesion</title>
        <description>The peel force to remove the sample</description>
        <time_frame>30 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data analysis per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>ChloraPrep</title>
            <description>Subject's back was applied with 2 skin preps (ChloraPrep and DuraPrep), one on each side of subject's back per randomization schedule.</description>
          </group>
          <group group_id="O2">
            <title>DuraPrep</title>
            <description>Subject's back was applied with 2 skin preps (ChloraPrep and DuraPrep), one on each side of subject's back per randomization schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Drape Adhesion</title>
            <description>The peel force to remove the sample</description>
            <units>grams-force</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="78.6" lower_limit="68.0" upper_limit="89.2"/>
                  <measurement group_id="O2" value="181.3" lower_limit="165.8" upper_limit="196.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Assessment on Ioban, ActiGard, Steri-Drape 2 Application Sites Respectively</title>
        <description>Visual assessment on skin after samples were removed. scale: 0 (no skin reaction), 4 (severe skin reaction)</description>
        <time_frame>30 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>The number of participants was determined to provide 80% power to detect a difference of 20% for the drape by prep comparisons</population>
        <group_list>
          <group group_id="O1">
            <title>ChloraPrep</title>
            <description>Subject's back was applied with 2 skin preps (ChloraPrep and DuraPrep), one on each side of subject's back per randomization schedule.</description>
          </group>
          <group group_id="O2">
            <title>DuraPrep</title>
            <description>Subject's back was applied with 2 skin preps (ChloraPrep and DuraPrep), one on each side of subject's back per randomization schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Skin Assessment on Ioban, ActiGard, Steri-Drape 2 Application Sites Respectively</title>
            <description>Visual assessment on skin after samples were removed. scale: 0 (no skin reaction), 4 (severe skin reaction)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Skin assessment on Ioban application site</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.67" spread="0.52"/>
                  <measurement group_id="O2" value="0.98" spread="0.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Skin assessment on ActiGard application site</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.31" spread="0.44"/>
                  <measurement group_id="O2" value="0.90" spread="0.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Skin assessment on Steri-Drape 2 application site</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.30" spread="0.43"/>
                  <measurement group_id="O2" value="0.95" spread="0.58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ChloraPrep, DuraPrep</title>
          <description>Subject's back was visually divide into 2. Applied each prep per manufacturer's instruction on either right or left of back according to randomization schedule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Restriction for PI to publish trial results without review and approval by sponsor</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All 22 subjects enrolled completed the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Gary Grove</name_or_title>
      <organization>cyberDERM Clinical Studies</organization>
      <phone>610-325-0112</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
